Table 1

Univariate analysis of variables affecting PD-L1 levels on EVs

VariablesEV-PD-L1loEV-PD-L1hiP value
(n=24)(n=19)
Gender0.101
 Male8 (33.3%)12 (63.3%)
 Female16 (66.7%)7 (36.8%)
 Age at allo-HSCT58.062.00.412
Remission status at allo-HSCT1.000
 CR7 (29.2%)6 (31.6%)
 PR/SD/PR17 (70.8%)13 (68.4%)
Donor type0.882
 Haploidentical related2 (8.3%)1 (5.3%)
 HLA-identical related7 (29.2%)4 (21.1%)
 Unrelated donor15 (62.5%)14 (73.7%)
GvHD prophylaxis0.572
 CSA/MMF10 (41.7%)10 (52.6%)
 CSA/MTX10 (41.7%)8 (42.1%)
 Cyclophosphamide/tacrolimus/MMF4 (16.7%)1 (5.26%)
Conditioning0.366
 Myeloablative12 (50.0%)6 (31.6%)
 Non-myeloablative12 (50.0%)13 (68.4%)
  • CR, complete remission; CSA, cyclosporine A; GvHD, graft-versus-host disease; HSCT, hematopoietic stem cell transplantation; MMF, mycophenolate mofetil; MTX, methotrexate; PR, partial remission; SD, stable disease.